Keterbatasan Penelitian Hasil dan Pembahasan

62 12. Nurman A, Huang MA. Perlemakan Hati Non Alkoholik. Universa Medicina.2007;264:205-15. 13. Neuschwander-Tetri BA. Nonalcoholic Steatohepatitis and the Metabolic Syndrome. Am J Med Sci.2005;3306:326-335 14. Podolsky Daniel K.. Infiltrative, Genetic, and Metabolic Diseases Affecting the Liver. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL eds.Harrison’s Principles of Internal Medicine. 16th ed. USA: McGraw-Hill; 2005. p1869-71 15. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The Epidemiology of Fatty Liver. European Journal of Gastroenterology Hepatology.2004;1611:1087-1093. 16. Lim JS, Snyder MM, Valente A, Schwarz JM, Lustig RH. The role of Fructose in the Pathogenesis of NAFLD and the Metabolic Syndrome. Nat. Rev. Gastroenterol. Hepatol..2010;70:251-264 17. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJ Med.2010;1030:71-83 A 18. Kuntz E. Hepatology Principles and Practice. 2nd ed. Germany. Springer; 2006 19. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal. Expert Rev Gastroenterol Hepatol.2009;34:445-451 20. Peverill W, Powell LW, Skolen R. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. Int. J. Mol. Sci..2014;150:8591- 8638 21. Wieckowska A, Feldstein AE. Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive. Seminars in Liver Disease.2008;284:386-395 22. National Intitutes of Health NIH. Nonalcoholic Steatohepatitis: 2006 23. Miskovitz P, Betancourt M. The Doctors Guide to Gastrointestinal Health. 1st ed. USA. John Wiley Sons, Inc.; 2005 24. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: A Practical Approach to Diagnosis and Staging. Frontline Gastroenterology.2014;50:211-218 25. Treeprasertsuk S, Björnsson E, Enders Felicity, Suwanwalaikom S, Lindor KD.NAFLD fibrosis score: A Prognostic Predictor for Mortality and Liver 63 Complications among NAFLD Patients. World Journal of Gastroenterology.2013;198:1219-1229 26. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease. Semin Liv Dis.2012;321:22-29 27. McCance KL, Huether SE, Brashers SE, Rote NS. Pathophysiology the Biologic Basis for Disease in Adults and Children. 6th ed. United States of America. Elsevier; 2010 28. Tortora GJ, Derrickson B. Principles of Anatomy Physiology. 13th ed. United States of America. John Wiley Sons, Inc.; 2012 29. Kamso S, Purwantyastuti, Juwita R. Dislipidemia Pada Lanjut Usia di Kota Padang. Makara Kesehatan.2002;62:55-58 30. Hatma RD. Lipid Profiles Among Diverse Ethnic Groups in Indonesia. Acta Med Indones-Indones J Intern Med.2011;431:4-11 31. Garg A. Insulin Resistance in the Pathogenesis of Dyslipidemia. Diabetes Care.1996;194:387-389 32. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of Dyslipidaemia in the Metabolic Syndrome. Postgrad Med J.2005;810:358- 366 33. National Institutes of Healt NIH. ATP III Guidelines At-A-Glance Quick Desk Reference:2001 34. Recommendations for the diagnosis and treatment of dyslipidemia. Can J Cardiol.2009;2211:1-5 35. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, etal. American Association of Clinical Endrocrinologists Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. AACE Lipid and Atherosclerosis Guidelines, Endocr Pract..2012;180:1-78 36. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-Alcoholic Fatty Liver Disease NAFLD and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients.2013;50:1544-1560 37. Souza MRDA, Diniz MDFFDM, Medeiros-Filho JEMD, Araujo MSTD . Metabolic Syndrome and Risk Factors for Non-Alcoholic Fatty Liver Disease. jan. Imar..2012;491:89-96